Report Content
Chapter 1 Methodology & Scope
1.1 Market scope & definitions
1.2 Research design
1.2.1 Research approach
1.2.2 Data collection methods
1.3 Base estimates & calculations
1.3.1 Base year calculation
1.3.2 Key trends for market estimation
1.4 Forecast model
1.5 Primary research and validation
1.5.1 Primary sources
1.5.2 Data mining sources
Chapter 2 Executive Summary
2.1 Industry 3600 synopsis
Chapter 3 Industry Insights
3.1 Industry ecosystem analysis
3.2 Industry impact forces
3.2.1 Growth drivers
3.2.1.1 Increasing prevalence of chronic diseases such as diabetes and obesity
3.2.1.2 Increasing R&D activities for developing novel therapeutics
3.2.1.3 Formulation advancements of oral GLP-1 receptor agonists
3.2.1.4 Increasing awareness about diagnosis and treatment options for diabetes
3.2.2 Industry pitfalls & challenges
3.2.2.1 Adverse effects associated with few GLP-1 agonist drugs
3.2.2.2 Product recalls by market players
3.3 Growth potential analysis
3.3.1 By drug class
3.3.2 By route of administration
3.3.3 By application
3.3.4 By distribution channel
3.4 Clinical trial analysis
3.5 Regulatory landscape
3.6 Porter’s analysis
3.7 PESTEL analysis
Chapter 4 Competitive Landscape, 2022
4.1 Introduction
4.2 Company matrix analysis
4.3 Global company market share analysis
4.4 Competitive positioning matrix
4.5 Strategic dashboard
Chapter 5 Market Estimates and Forecast, By Drug Class (USD Million)
5.1 Key trends
5.2 Semaglutide
5.3 Dulaglutide
5.4 Liraglutide
5.5 Exenatide
5.6 Other drug classes
Chapter 6 Market Estimates and Forecast, By Route of Administration (USD Million)
6.1 Key trends
6.2 Parenteral
6.3 Oral
Chapter 7 Market Estimates and Forecast, By Application (USD Million)
7.1 Key trends
7.2 Type 2 diabetes mellitus
7.3 Obesity
7.4 Other applications
Chapter 8 Market Estimates and Forecast, By Distribution Channel (USD Million)
8.1 Key trends
8.2 Hospital pharmacies
8.3 Retail pharmacies
8.4 Online pharmacies
Chapter 9 Market Estimates and Forecast, By Region (USD Million)
9.1 Key trends
9.2 North America
9.2.1 U.S.
9.2.2 Canada
9.3 Europe
9.3.1 Germany
9.3.2 UK
9.3.3 France
9.3.4 Spain
9.3.5 Italy
9.3.6 Switzerland
9.3.7 Rest of Europe
9.4 Asia Pacific
9.4.1 China
9.4.2 Japan
9.4.3 India
9.4.4 Australia
9.4.5 South Korea
9.4.6 Rest of Asia Pacific
9.5 Latin America
9.5.1 Brazil
9.5.2 Mexico
9.5.3 Rest of Latin America
9.6 Middle East & Africa
9.6.1 South Africa
9.6.2 Saudi Arabia
9.6.3 Rest of Middle East & Africa
Chapter 10 Company Profiles
10.1 Eli Lilly and Company
10.2 Sanofi
10.3 Novo-Nordisk A/S
10.4 AstraZeneca
10.5 Pfizer, Inc.
10.6 Amgen, Inc.
10.7 Innovent Biologics, Inc.
10.8 PegBio Co., Ltd.
10.9 Sun Pharmaceutical Industries Ltd.
10.10 Boehringer Ingelheim International GmbH
